Takeda’s epilepsy drug misses main goals in late-stage trials



The news comes less than a month after the state’s largest biotech employer disclosed it would lay off employees and focus on its most recently approved drugs and late-stage programs.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *